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Abstract
Outcomes and direct treatment costs with novel oral anticoagulants compared
to clinic-monitored warfarin for stroke prevention in atrial fibrillation
Sarah Elizabeth Hulvershorn, M.S.P.S.
The University of Texas at Austin, 2014
Supervisor: Karen L. Rascati; James P. Wilson
Objectives: To describe patient characteristics and evaluate costs and outcomes of novel
oral anticoagulants compared to clinic-monitored warfarin for the prevention of stroke
and systemic embolism in patients with atrial fibrillation within the Scott & White
Healthcare system.
Methods: Patients with atrial fibrillation, CHADS2 score ≥ 1, and a prescription claim
for dabigatran, rivaroxaban, or warfarin between 2010 and 2012 were evaluated over 12
months.  Patients in the warfarin cohort were enrolled in an Anticoagulation Clinic.
Patients were matched 1:1 for age, CHADS2, and gender for comparisons between
groups. Baseline characteristics, medication adherence, occurrence of adverse events, and
treatment costs were compared using inferential statistics.  Anticoagulation control was
assessed for patients in the warfarin cohort.
Results: 141 and 471 patients met criteria for the novel cohort group and the warfarin
group, respectively.  After matching, 136 remained in each cohort. Prior to matching,
vcompared to the warfarin cohort, the novel anticoagulant cohort had a higher proportion
of male patients (63% versus 49%), and lower average CHADS2 score (2.65 versus 3.30),
while average age in both cohorts was similar (75 years). Matched cohorts had similar
adherence rates (88% for novel versus 87% for warfarin). After matching, annual
medication cost in 2014 US dollars for dabigatran or rivaroxaban averaged $2,658 (SD
$1,494) compared to $1,066 (SD $633) for warfarin, including monitoring costs.  Annual
total all-cause healthcare costs averaged $23,711 (SD $22,910) for dabigatran or
rivaroxaban, compared to $18,248 (SD $24,184) for warfarin. For the 96 warfarin
patients with INR values, time in therapeutic range averaged 70.4%.
Conclusion: Compared to clinic-monitored warfarin, more men than women were
prescribed new oral anticoagulants and these patients averaged a lower CHADS2 score.
After matching, patient adherence was high and comparable between groups.
Anticoagulation control for warfarin patients was similar to clinical trials.  Annual
medication cost was significantly greater for new oral anticoagulants than clinic-
monitored warfarin, including INR monitoring costs.  Total annual all-cause healthcare
costs were significantly greater for patients taking new oral anticoagulants compared to
warfarin, although too few adverse events occurred to draw conclusions regarding event
rates and costs of ischemic stroke and major bleeds.
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1CHAPTER 1: INTRODUCTION
Atrial Fibrillation
Atrial fibrillation is the most common sustained cardiac arrhythmia, estimated to affect
2.2 million Americans. 1 Atrial fibrillation occurs more often in men, patients with more severe
heart failure, and incidence increases dramatically with age, with an 8% incidence rate in patients
>80 years old.1,2 Due to the aging population and improved survival of patients with
cardiovascular disease, it is projected that the prevalence of atrial fibrillation in the United States
will climb to over 12 million by the year 2050.1,2
Physiologically, atrial fibrillation is characterized by rapid, disorganized electrical
activity (400 to 600 beats per minute) in the atria of the heart, leading to an irregularly irregular
supraventricular heart rhythm.1 The etiology of atrial fibrillation is often cardiogenic in nature,
occurring frequently in patients with ischemic heart disease, heart failure, hypertension,
congenital abnormalities, and valvular heart disease.1 Noncardiogenic causes of atrial fibrillation
include states of high adrenergic tone such as hyperthyroidism, acute infection, alcohol
withdrawal, or post-surgery.1 Atrial fibrillation may be asymptomatic, but patients can also
experience clinical manifestations such as rapid heart rate, palpitations, fatigue, dizziness,
shortness of breath, and worsening heart failure.1
Thromboembolic Events
Patients with atrial fibrillation are at increased risk of thromboembolic events, due to
pooling of blood in the atria leading to subsequent thrombus formation.1 Stroke is the most
concerning of thromboembolic events associated with atrial fibrillation.  Atrial fibrillation is a
2strong independent predictor for ischemic stroke, and is associated with a fivefold increase in
risk.2 The use of oral antithrombotic agents is the mainstay of therapy in the prevention of stroke
and systemic embolism in patients with atrial fibrillation. However, antithrombotic therapy is
associated with increased risk of bleeding, therefore the underlying benefit of antithrombotic
therapy depends on the risk of stroke.3,4 Although there are several indices available to estimate
baseline risk of stroke in patients with atrial fibrillation, the CHADS2 score has been widely
adopted by clinicians and is currently the most validated risk scheme, as it has been tested in at
least 10 different cohorts since its original development.4 CHADS2 is an acronym for the risk
factor criteria used to determine the score (Congestive heart failure, Hypertension Age, Diabetes,
and prior Stroke). The CHADS2 score consists of a summary score of 0-6 based on risk factors
for stroke in patients with atrial fibrillation, with 1 point each given for congestive heart failure,
history of hypertension, age ≥75, and diabetes mel litus, and 2 points assigned for history of
stroke or transient ischemic attack.3 The Antithrombotic Therapy and Prevention of Thrombosis,
9th edition, American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice
Guidelines published in 2012 recommend aspirin as the antithrombotic agent of choice for atrial
fibrillation patients at low risk of stroke (CHADS2 = 0), and oral anticoagulant therapy for
patients at intermediate to high risk of stroke (CHADS2 ≥ 1).4
Warfarin Therapy
The use of oral anticoagulation is the mainstay of therapy in the prevention of stroke and
systemic embolism in patients with atrial fibrillation.1 For over 50 years, warfarin was the only
oral anticoagulant available for clinical use in the U.S.5 Warfarin acts as a vitamin K antagonist,
inhibiting the production of vitamin K-dependent clotting factors (factor VII, IX, X, and
3prothrombin), thereby preventing initial thrombus formation and development.1 A major
limitation of warfarin is a wide inter-patient variability in dose-response due to a variety of
factors.1,5 Therapeutic response to warfarin is affected by genetic variability in both the CYP2C9
enzyme, affecting hepatic metabolism of warfarin, as well as vitamin K epoxide reductase
(VKOR), which affects the pharmacodynamics of warfarin.1,5 Variations in oral intake of dietary
vitamin K impacts the effectiveness of warfarin.1 Warfarin has numerous drug-drug interactions
caused by a variety of mechanisms, including other drugs that induce or inhibit CYP2C9.1 The
primary adverse effect of warfarin (and the result of over-anticoagulation) is hemorrhage, such as
gastrointestinal bleeding, bruising, and most severe, intracranial hemorrhage.1
Due to variability in therapeutic response and the narrow therapeutic index of the drug,
warfarin requires frequent laboratory monitoring and dosing adjustments.  The anticoagulation
effect of warfarin is measured by prothrombin time (PT), which measures the amount of time
required for clot formation upon addition of a reagent to a plasma sample.1 Due to variability in
the sensitivity of the reagent used to measure PT, the World Health Organization (WHO)
developed a reference reagent in the 1970s and recommended the use of a corrected
prothrombin-time ratio called the International Normalized Ratio (INR) to monitor warfarin
therapy.1 For stroke prevention in atrial fibrillation, the recommended therapeutic INR range is
typically 2.0 – 3.0, with a target INR of 2.5.6 INR testing is frequent upon initiation of warfarin
therapy or upon dose adjustment (i.e., every few days to weekly), occurs every 4 weeks once
INRs and dosing are stable, but may extend up to 12 week intervals in patients with consistently
stable INRs.6 The management of patients experiencing elevated INRs or bleeding depends on
severity, and ranges from warfarin dose reduction or omission to administration of oral vitamin
4K, intravenous vitamin K, fresh frozen plasma, prothrombin complex, or Recombinant Factor
VIIa.6
Sorensen and colleagues demonstrated that clinical and cost outcomes of warfarin are
strongly dependent on the quality of anticoagulation, and as INR control improves, stroke rates
decrease, quality-adjusted life years (QALYs) increase, and per-patient costs decrease.7 The
quality of a patient’s anticoagulation management can be assessed by examining INRs over time.
Time in Therapeutic Range (TTR) is often calculated as the proportion of days a patient’s INR is
in therapeutic range over the total number of days in the follow-up period, as proposed by
Rosendaal et. al.8 TTR has been reported in clinical trials ranging from 55-66%, although studies
in community settings have reported TTRs closer to 50%.9
New Oral Anticoagulants
Dabigatran and rivaroxaban are new oral anticoagulants that became available in 2010
and 2012, respectively, as alternative therapy to warfarin for the prevention of stroke and
systemic embolism in patients with non-valvular atrial fibrillation.  Pharmacologically,
dabigatran and rivaroxaban target different areas of the anticoagulation pathway than warfarin
(Figure 1.1).  These novel oral anticoagulants provide the advantage of fixed dosing and no
laboratory monitoring, potentially leading to improved patient compliance.10
Dabigatran exerts its action as a direct thrombin inhibitor that prevents thrombin-induced
platelet aggregation, thereby reducing the ability of thrombin to form a clot.5 The pivotal study
for dabigatran was the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY)
study, which was a randomized clinical trial of 18,113 patients with atrial fibrillation and risk of
5Figure 1.1:  Site of Action of Oral Anticoagulants in the Coagulation Cascade11
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6stroke comparing fixed-dose dabigatran to dose-adjusted warfarin.12 The primary outcome of
RE-LY was stroke or systemic embolism, with major hemorrhage as the primary safety
outcome.12 Warfarin was adjusted to an INR of 2.0-3.0, with a reported TTR of 64%. The mean
CHADS2 score for patients in RE-LY was 2.1.  Dabigatran showed decreased annual rates of
stroke and systemic embolism compared to warfarin (1.11% versus 1.69%, respectively, p<0.001
for superiority).12 Dabigatran was shown to have similar annual rates of major hemorrhage
compared to warfarin (3.11% versus 3.36%, respectively, p=0.31).12 However, dabigatran had
lower annual rates of intracranial bleeding and life-threatening bleeding compared to warfarin
(0.74% versus 0.30%, and 1.80% versus 1.45%, respectively) (p<0.05 for all comparisons).12
Dabigatran was found to have higher annual rates of gastrointestinal bleeding than warfarin
(1.51% versus 1.02% respectively, p<0.001).12
Rivaroxaban is a direct factor Xa inhibitor, and exerts its action by reducing the
production of thrombin, thus inhibiting thrombin-induced platelet activation and fibrin clot
formation.5 The pivotal study for rivaroxaban was the Rivaroxaban Once Daily Oral Direct
Factor Xa inhibition Compared with Vitamin K Antagonist for the Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-AF) study.  ROCKET-AF was a double-blind,
randomized clinical trial of 14,264 patients with atrial fibrillation plus two additional risk factors
for embolic events, comparing fixed-dose rivaroxaban to dose-adjusted warfarin.13 The primary
outcome of ROCKET-AF was stroke or systemic embolism, and the primary safety endpoint was
clinically relevant bleeding.13 Warfarin was adjusted to an INR of 2.0-3.0, with a reported TTR
of 55%. The mean CHADS2 score for patients in ROCKET-AF was 3.5.  Rivaroxaban was
shown to be non-inferior to warfarin in annual rates of stroke and systemic embolism (1.7%
7versus 2.2%, respectively, p<0.001 for noninferiority).13 Rivaroxaban was shown to have similar
annual rates of major hemorrhage compared to warfarin (3.6% versus 3.4%, respectively,
p=0.58).13 However, rivaroxaban had lower annual rates of intracranial bleeding and fatal
bleeding compared to warfarin (0.5% versus 0.7%, and 0.2% versus 0.5%, respectively) (p<0.05
for all comparisons).13 Rivaroxaban was found to have higher annual rates of gastrointestinal
bleeding than warfarin (3.2% versus 2.2% respectively, p<0.001).13
In summary, clinical trials showed dabigatran to be clinically superior to warfarin in
decreased rate of stroke and systemic embolism in patients with atrial fibrillation, while
rivaroxaban was shown to be similar in efficacy compared to warfarin.12,13 Both dabigatran and
rivaroxaban were shown to have similar rates of major hemorrhage compared to warfarin, but
less risk of intracranial bleeding.12,13 The advantages of these agents include the convenience of
fixed dosing due to more predictable pharmacology, less dietary restrictions and drug-drug
interactions than warfarin, and no laboratory monitoring. However, the new oral anticoagulants
are not without limitations.  There are currently no widely available laboratory tests to correlate
drug concentration and level of anticoagulation.  This is due to insensitivity or oversensitivity of
the new oral anticoagulants to currently available laboratory tests, nonlinear relationships to drug
concentrations, and lack of clinical trial data linking clinical outcomes to drug concentration
levels or clotting results.5 There is currently no antidote to dabigatran or rivaroxaban for
management of major bleeding, overdose, or urgent surgery or invasive procedures. Current
management of major bleeding includes empirical strategies, such as discontinuation of the drug,
volume or red blood cell replacement, local measures such as pressure or cautery, or activated
charcoal to reduce gastrointestinal absorption.5,9 Dabigatran is dialyzable, presenting another
8potential management option, but rivaroxaban is highly plasma protein bound and dialysis would
not be an appropriate option.9 Additionally, the new oral anticoagulants have a rapid
pharmacokinetic onset and offset, which may be attractive, but also makes patient compliance
imperative.9 In fact, the FDA has issued black box warnings on dabigatran and rivaroxaban
warning that premature discontinuation of the drugs can increase risk of thromboembolic events.
Additionally, dabigatran and rivaroxaban are priced at significantly higher acquisition costs
compared to warfarin.
Cost-Effectiveness Studies
Using data from published clinical trials, several economic analyses have been conducted
in hypothetical patient populations to evaluate the cost-effectiveness of dabigatran or
rivaroxaban compared to warfarin in patients with nonvalvular atrial fibrillation.
The cost-effectiveness of dabigatran was examined in a Markov decision analysis model
by Freeman, et al. and showed dabigatran provided an additional 0.56 quality-adjusted life years
(QALYs) over warfarin in patients age 65 and older with nonvalvular atrial fibrillation and at an
increased risk of stroke (CHADS2 ≥ 1).14 The incremental cost-effectiveness ratio showed that
dabigatran costs $45,372 (in 2008 U.S. dollars) per QALY gained compared to warfarin, with
cost-effectiveness improving with increased risk of stroke and intracranial bleeding.14 Assuming
a willingness-to-pay threshold of $50,000 per QALY gained, this finding suggests that
dabigatran may be a cost-effective alternative to dose-adjusted warfarin in this population.
However, it is important to note the model was sensitive to dabigatran costs, as costs in the
analysis were estimated from pricing in the United Kingdom.14 Additionally, event rates used in
this analysis were primarily derived from the RE-LY trial.14
9Shah et al. conducted a Markov decision analysis model comparing various
antithrombotic therapies for the treatment of atrial fibrillation and showed that for 70-year-old
patients at moderate risk of stroke, dabigatran provided additional 0.25 QALYs over warfarin at
a cost of $86,000 (in 2010 U.S. dollars) per QALY gained.15 Although the base-case scenario
estimate is higher than the commonly used willingness-to-pay threshold of $50,000 per QALY
gained, the model was found to be sensitive to risk of stroke, bleed, and INR control of warfarin.
For patients with moderate risk of stroke (CHADS2 = 1 or 2), warfarin was cost-effective, unless
the risk of hemorrhage was high (6%/year) or INR control was poor (TTR <57.1%).15 For
patients with high risk of stroke (CHADS2 ≥ 3), dabigatran was cost-effective, unless INR
control was excellent (TTR >72.6%), in which case warfarin was cost-effective.15 Dabigatran
efficacy for this analysis was solely based on the RE-LY trial.
The cost-effectiveness of rivaroxaban was examined by Lee et al.16 Their Markov
decision analysis model utilized ROCKET-AF study data and found that for 65-year-old atrial
fibrillation patients at high risk for stroke (CHADS2 = 3), rivaroxaban provided an additional
0.22 QALYs over warfarin for an additional lifetime treatment cost of $5,912 (in 2011 U.S.
dollars).16 This results in an incremental cost-effectiveness ratio of $27,498 per QALY gained.16
Although this is below the willingness to pay threshold of $50,000, the model was sensitive to
rates of intracranial hemorrhage, stroke, and cost of rivaroxaban, as well as time horizon.
Rivaroxaban was found to be cost-effective in 80% of 10,000 Monte Carlo iterations at a
willingness-to-pay threshold of $50,000 per QALY.16
Deitelzweig and colleagues conducted an economic analysis using data from both the
RE-LY and ROCKET-AF study, estimating one-year medical costs to be lower for atrial
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fibrillation patients taking dabigatran or rivaroxaban (-$179 and -$89, respectively, in 2010 U.S.
dollars) compared to warfarin.17 Of 10,000 Monte-Carlo iterations, one-year medical costs were
shown to be less than warfarin 92.6% of the time with dabigatran and 79.8% of the time with
rivaroxaban.17 Of note, this study demonstrated increased one-year medical cost of major
bleedings (excluding hemorrhagic stroke) with dabigatran and rivaroxaban (+$31 and +$108,
respectively) compared to warfarin.17 Medical costs in this study were driven by clinical
outcomes, as drug costs and monitoring costs were excluded from the analysis.
Harrington et al. also used data from the RE-LY and ROCKET-AF studies to conduct a
Markov model decision analysis in nonvalvular atrial fibrillation patients age 70 at an increased
risk of stroke (CHADS2 ≥ 1).18 Warfarin was found to have the lowest lifetime costs ($77,813, in
2012 U.S. dollars) followed by rivaroxaban ($78,738) and dabigatran ($82,719).18 Dabigatran
provided an additional 0.44 QALY over warfarin while rivaroxaban provided an additional 0.29
QALY.18 Both dabigatran and rivaroxaban were shown to be  cost-effective compared to
warfarin, with incremental cost-effectiveness ratios of $3,190 and $11,150, respectively.18 Monte
Carlo simulation showed dabigatran to be cost-effective in 40% of iterations, rivaroxaban in 14%
of iterations, and warfarin in 0% iterations.18 Cost-effectiveness in this model was dependent on
the cost of the novel oral anticoagulants and on neurological events associated with
rivaroxaban.18
Study Rationale
Oral anticoagulants are the mainstay of prevention of stroke in patients with atrial
fibrillation.  For over 50 years, warfarin was the only oral anticoagulant available for clinical use
in the U.S.  Limitations of warfarin include wide inter-patient variability in dose response and a
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narrow therapeutic index requiring frequent INR monitoring.  Novel oral anticoagulants have
recently become available on the market that are similar in safety and efficacy to warfarin but
have the advantage of more predictable pharmacokinetic profiles and no laboratory monitoring.
Limitations to the new oral anticoagulants include lack of specific antidotes and significantly
higher acquisition costs compared to warfarin.  Several studies have shown potential cost-
effectiveness of novel oral anticoagulants compared to warfarin in certain patient populations
based on economic modeling from clinical trial data.   However, the current literature is deficient
in the evaluation of the cost-effectiveness of novel oral anticoagulants compared to warfarin in
“real-world settings”, which may differ from results seen in clinical trials due to more inclusive
patient populations, and real-world patient compliance and INR control.  The findings of this
study will contribute significantly to the literature by describing patient characteristics,
quantifying the incidence of major bleeds, rates of ischemic stroke, and the costs of treatment of
novel oral anticoagulants compared to clinic-monitored warfarin for stroke prevention in patients
with atrial fibrillation in a real-world healthcare system. Results may be incorporated into future
models.
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CHAPTER 2: METHODS
Study Objectives and Hypotheses
This study evaluated the cost-effectiveness of novel oral anticoagulants compared to clinic-
monitored warfarin for prevention of stroke and systemic embolism in patients with atrial
fibrillation within the Scott & White Healthcare system.   The specific objectives of this study
were:
1.) To determine if patient characteristics (age, gender, or CHADS2 score) differ between
patients taking novel oral anticoagulants (dabigatran or rivaroxaban) versus clinic-
monitored warfarin.
2.) To determine if patient adherence to oral anticoagulant medication differs between
patients taking novel oral anticoagulants (dabigatran or rivaroxaban) versus clinic-
monitored warfarin.
3.) To determine if incidence of major bleeds (defined as requiring inpatient hospitalization)
differs between patients taking novel oral anticoagulants (dabigatran or rivaroxaban)
versus clinic-monitored warfarin.
4.) To determine if incidence of ischemic stroke differs between patients taking novel oral
anticoagulants (dabigatran or rivaroxaban) versus clinic-monitored warfarin.
5.) To assess direct treatment costs with novel oral anticoagulants (dabigatran or
rivaroxaban) compared to clinic-monitored warfarin.
6.) To assess INR control in patients taking clinic-monitored warfarin within the Scott &
White Healthcare System.
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This study addressed the following hypotheses:
H01:  There is no statistical difference in patient characteristics (age, gender, or CHADS2
score) between patients taking novel oral anticoagulants (dabigatran or rivaroxaban)
versus clinic-monitored warfarin.
H02:  There is no statistical difference in patient adherence to oral anticoagulant
medication between patients taking novel oral anticoagulants (dabigatran or rivaroxaban)
versus clinic-monitored warfarin.
H03:  There is no statistical difference in the incidence of major bleeds (requiring
inpatient hospitalization) between patients taking novel oral anticoagulants (dabigatran or
rivaroxaban) versus clinic-monitored warfarin.
H04:  There is no statistical difference in the incidence of ischemic stroke between
patients taking novel oral anticoagulants (dabigatran or rivaroxaban) versus clinic-
monitored warfarin.
H05:  There is no statistical difference in total all-cause direct treatment costs for cohorts
with novel oral anticoagulants (dabigatran or rivaroxaban) compared to clinic-monitored
warfarin.
Data Source
Retrospective data were obtained from Scott & White Healthcare.  Scott & White
Healthcare is an integrated health system in Central Texas.  The regional healthcare system is a
1,200 physician staff-model group practice which includes 12 hospitals and over 45 regional
clinics (Scott & White Clinics) with 2 million patient visits annually.  Scott & White Health Plan
is a 220,000 covered lives staff-model nonprofit health plan, including 20,000 Medicare Part D
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members and covering 50 counties in the Central Texas Region.  Scott & White operates its own
pharmacy benefit management (PBM) program, which includes an additional 45,000 member
lives.  Additionally, Scott & White operates a regional network of retail pharmacies.
The Scott & White Anticoagulation Clinic has been in operation since 1995 and focuses on
outpatient management of warfarin therapy for patients across Central Texas. The multi-
disciplinary clinic is staffed by pharmacists, nurses, and nurse practitioners who have been
specially trained in anticoagulation therapy. Physician medical directors provide medical and
administrative guidance for the Anticoagulation Clinic, which included an internal medicine
physician and a hematologist during the time period of this study (January 2010 through
December 2013). In addition to outpatient clinic operations, the Anticoagulation Clinic also
provides a hospital service for clinic patients to smooth the transition of care from the inpatient
to outpatient setting.
Patients are enrolled in the Anticoagulation Clinic upon physician referral for
management of warfarin therapy for a variety of indications. Anticoagulation therapy
monitoring and dose adjustments are based on a physician-approved protocol, and include
patient education, screening for drug-drug interactions, drug-food interactions, and changes in
health status affecting anticoagulation, prothrombin time (PT) and International Normalized
Ratio (INR) monitoring, and subsequent dose adjustments to optimize therapy. PT and INR
monitoring is performed by fingerstick in the office at point-of-care in about 70% of
patients. Nursing home, home health, and out-of-town patients are monitored for PT/INR
remotely via laboratory venipuncture and comprise 30% of patients.
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This study was approved via expedited review by the Scott & White and The University
of Texas Institutional Review Boards.
Study Design
The study was an intent-to-treat, retrospective, quasi-experimental design utilizing
matched cohorts to allow for between-group comparisons of clinical and economic outcomes.
Pharmacy claims, medical claims, electronic medical records, and health plan enrollment data
were evaluated from January 1, 2010 to December 31, 2013.
Study Population
Patients were required to be 18 years or older with at least one diagnosis code for atrial
fibrillation (ICD-9 427.31) and a CHADS2 score ≥ 1 in order to be included in the analysis.
Patients with at least one pharmacy claim for dabigatran or rivaroxaban between January 1, 2010
and December 31, 2012 were included in the novel oral anticoagulant cohort.   Patients included
in the warfarin cohort must have had at least one pharmacy claim for warfarin between January
1, 2010 and December 31, 2012 and be enrolled in the Scott & White Anticoagulation Clinics
located in the cities of Temple, Gatesville, Taylor, or Killeen, Texas.
The date of the first claim for dabigatran, rivaroxaban, or warfarin between January 1,
2010 and December 31, 2012 was considered the index date.  Patients were required to have
continuous enrollment in Scott & White Health Plan for at least 12 months post-index.
Patients in the novel oral anticoagulant cohort were matched 1:1 to patients meeting
criteria for the warfarin cohort, based on gender, age at index, and CHADS2 score.
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Outcome Measures
1.) Patient characteristics were evaluated based on age at index (continuous variable), gender
(male or female), and baseline CHADS2 stroke-risk index (score of 0 – 6) based on ICD9
codes (see Appendix A) from historical data in electronic medical records.
2.) Medication possession ratio (MPR) was calculated from prescription claims data to
assess patient adherence to the index drug. MPR is a continuous variable defined as the
number of days of medication supplied divided by the number of days from the first
prescription of index drug filled to the date of the last index drug refilled during the 12
months post-index period19 and was calculated as follows:
MPR = total days supply of medication dispensed
last prescription date – first prescription date + last prescription days of supply
3.) Incidence of major bleeds was extracted from inpatient claims with a primary ICD-9 code
for hemorrhagic events (See Appendix B) within 12 months post-index.
4.) Incidence of stroke was extracted from inpatient claims with a primary ICD-9 code for
ischemic stroke (ICD-9 433.xx – 435.xx) within 12 months post-index.
5.) Direct treatment costs were summed for the 12 months post-index follow-up period using
the following cost parameters:
a. Cost of index medication from pharmacy claims adjusted to 2014 U.S. dollars
based on average wholesale price (AWP) from Medi-Span®
b. Cost of monitoring warfarin via anticoagulation clinic as a sum of the following
parameters per documented point-of-care laboratory INR testing:
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 2014 Centers for Medicare and Medicaid Services (CMS) reimbursement
rate for CPT 85620 “prothrombin time” and CPT 99213 “15 minute office
visit”
 2014 cost of one iStat INR testing cartridge
 20 minutes of staff labor cost for a registered nurse, as estimated by the
2012 median pay reported by the Bureau of Labor Statistics20 adjusted to
2014 dollars using a 4% average medical inflation rate.21
c. Costs to treat clinical adverse events estimated from the total cost for each claim
with an inpatient visit with a primary ICD-9 code for ischemic stroke (ICD-9
433.xx – 435.xx) or bleed (Appendix B).  Costs were adjusted to 2014 U.S.
dollars at a 4% annual medical inflation rate.21
6.) Time in therapeutic range (TTR) was calculated to assess INR control for patients in the
warfarin cohort. TTR is a continuous variable defined as the proportion of time that the
international normalized ratio (INR) was within therapeutic range.   For the purposes of
this study, the therapeutic range was assumed to be an INR between 2.0 and 3.0,
consistent with 2012 ACCP guidelines.6 TTR was calculated by the method proposed by
Rosendaal et. al,8 whereby INR values between two INR assessments are estimated using
linear interpolation, and the TTR is defined as follows:
Proportion of TTR = # of patient days within specified range
total patient days in follow-up period
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Statistical Analysis
 Descriptive statistics (mean and standard deviation or median and interquartile range)
will be used to characterize demographic data before and after matching.
 Chi-square analyses will be conducted for categorical variable comparisons between
groups (e.g., incidence of major bleeds and ischemic stroke).
 Mann-Whitney U tests will be conducted for nonparameteric continuous variable
comparisons between groups (e.g., direct treatment costs).
 Statistical analyses will be computed using SAS 9.2 (SAS Institute Inc, Cary, North
Carolina) and IBM SPSS Statistics Version 21 for Windows.
 A value of p<0.05 will be used to determine statistical significance.
Feasibility Analysis
 Sample size calculations were performed using G*Power 3.1.9.2 software:
o Using a conventional estimation for small effect size (w = 0.1), a total sample size
of 785 would be required to determine a difference in rate of stroke or major
bleed between treatment groups using Chi-Square analyses, assuming an alpha of
0.05 and power of 0.80.
o Using published annual stroke rates from RE-LY yielded an effect size of w =
0.05, which would require a total sample size of 3,140 to detect a difference in
rate of stroke between treatment groups using Chi-Square analyses, assuming an
alpha of 0.05 and power of 0.80.
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o Using published annual bleed rates from RE-LY yielded an effect size of w =
0.01, which would require a total sample size of 19,623 to detect a difference in
rate of major bleed between treatment groups using Chi-Square analyses,
assuming an alpha of 0.05 and power of 0.80.
 Preliminary sample sizes (prior to application of inclusion/exclusion criteria):
o 254 unique Scott & White Health Plan members initiated dabigatran or
rivaroxaban between January 1, 2010 and December 31, 2012.
o 899 unique Scott & White Health Plan members had a claim for warfarin and
were enrolled in Scott & White Anticoagulation Clinics in the cities of Temple,
Gatesville, Taylor, and Killeen, Texas between January 1, 2010 and December 31,
2012.
 Preliminary event rates (prior to application of inclusion/exclusion criteria):
o Of the 254 members with a claim for dabigatran or rivaroxaban:
 34 had an inpatient medical claim with a primary diagnosis of bleed
between January 1, 2010 and December 31, 2013.
 30 had an inpatient medical claim with a primary diagnosis of ischemic
stroke between January 1, 2010 and December 31, 2013.
o Of the 899 unique members with a claim for warfarin and enrolled in
anticoagulation clinic:
 114 had an inpatient medical claim with a primary diagnosis of bleed
between January 1, 2010 and December 31, 2013.
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 109 had an inpatient medical claim with a primary diagnosis of ischemic
stroke between January 1, 2010 and December 31, 2013.
 Although sample size may be a limitation in this study for the statistical comparison of
rare events (e.g., incidence of major bleeds and ischemic stroke), this study will still
contribute to the literature with regards to comparison of direct treatment costs,
adherence rates (MPR), and patient characteristics (e.g., age, gender, CHADS2 score)
between novel oral anticoagulants and clinic-monitored warfarin patients, as well as
assessing INR control (TTR) of clinic-monitored warfarin patients in a real-world
population.
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CHAPTER 3: RESULTS
Patient Selection
A total of 758 patients met the inclusion criteria for this study.  Among these, 141
patients met criteria for inclusion in the novel oral anticoagulant cohort, and 617 met criteria for
inclusion in the warfarin cohort.  After conducting a 1:1 match based on gender, age at index,
and CHADS2 score, the final study cohort included 136 patients in each group (Figure 3.1).
Figure 3.1: Flow-chart of patient identification
Novel Oral
Anticoagulants
Prescription Claim
(1/1/2010 – 12/31/2012)
n = 254
Removed duplicate index medications
n = 235
Removed patients with insufficient
EMR data
n = 229
Atrial fibrillation diagnosis
n=183
CHADS2 ≥ 1
n = 174
12 months post-index health plan
enrollment
n = 141
Matched 1:1 for gender, age at index, and CHADS2 score
n = 136 in each group
Warfarin
Prescription Claim
(1/1/2010 – 12/31/2012)
n = 3,382
Enrolled in Anticoagulation Clinic
n = 899
Removed duplicate index medications
n = 897
Atrial fibrillation diagnosis
n = 675
CHADS2 ≥ 1
n = 662
12 months post-index health plan
enrollment
n = 617
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Demographic Characteristics
Demographic information for the 758 patients meeting inclusion criteria prior to
matching is described in Table 3.1. An independent groups t-test showed no significant
difference in mean age at index (in years) between patients taking novel oral anticoagulants
(75.1, SD = 10.0) and warfarin (76.1, SD = 9.7) (t = 1.116; df = 203.963; p = 0.266).
A chi-square analysis revealed a significant relationship between patient gender and
medication cohort (X2 = 9.443; df = 1; p = 0.002). A greater proportion of males (63.1%)
comprised the novel anticoagulant cohort than females (36.9%). In the warfarin cohort, gender
proportions were almost equal (males = 48.8%; females = 51.2%).
A Mann-Whitney U test showed a significant difference in CHADS2 score between
patients taking novel oral anticoagulants (median = 2.0; mean = 2.65; SD = 1.24) and warfarin
(median = 3.0; mean = 3.30; SD = 1.35) (Z = -5.317; p < 0.001).
Table 3.1:  Baseline Characteristics by Cohort Prior to Matching
Novel Anticoagulant
(n = 141)
Warfarin
(n = 617) p-value
Age at index (years)
mean (SD) 75.06 (10.029) 76.10 (9.688) 0.266a
Gender
Male, n (%)
Female, n (%)
89 (63.1)
52 (36.9)
301 (48.8)
316 (51.2)
0.002b
CHADS2 score
1, n (%)
2, n (%)
3, n (%)
4, n (%)
5, n (%)
6, n (%)
22 (15.6)
57 (40.4)
26 (18.4)
22 (15.6)
12 (8.5)
2 (1.4)
54 (8.8)
127 (20.6)
185 (30.0)
117 (19.0)
97 (15.7)
37 (6.0)
<0.001c
a Independent sample t-test (t = 1.116; df = 203.963)
b Chi-Square analysis (X2 = 9.443; df = 1)
c Mann-Whitney U (Z = -5.317)
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To form the final study cohort, patients in the novel anticoagulant cohort were matched
1:1 with patients in the warfarin cohort based on gender and CHADS2 score, and a difference of
≤2 years of age at index. Demographic information for the 272 patients meeting inclusion
criteria after matching is described in Table 3.2. An independent groups t-test showed no
significant difference in mean age at index (in years) between patients taking novel oral
anticoagulants (75.4, SD = 9.4) and warfarin (75.1, SD = 9.1) (t = -0.275; df = 269.785; p =
0.784). After matching, the proportions of patients by gender and in each CHADS2 category
were identical. Average CHADS2 score for both cohorts after matching was 2.71.
Table 3.2:  Baseline Characteristics by Cohort After Matching
Novel Anticoagulant
(n = 136)
Warfarin
(n = 136) p-value
Age at index (years)
mean (SD) 75.43 (9.401) 75.13 (9.140) 0.784a
Gender
Male, n (%)
Female, n (%)
85 (62.5)
51 (37.5)
85 (62.5)
51 (37.5)
1.0b
CHADS2 score
1, n (%)
2, n (%)
3, n (%)
4, n (%)
5, n (%)
6, n (%)
18 (13.2)
56 (41.2)
26 (19.1)
22 (16.2)
12 (8.8)
2 (1.5)
18 (13.2)
56 (41.2)
26 (19.1)
22 (16.2)
12 (8.8)
2 (1.5)
1.0c
a Independent sample t-test (t = -0.275; df = 269.785)
b Chi-Square analysis (X2 = 0.000; df = 1)
c Mann-Whitney U (Z = 0.000)
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Anticoagulant Adherence
Medication Possession Ratio (MPR) was calculated from prescription claims data over
the 12 months post-index period to assess patient adherence to the index drug.  Overall MPR was
found to be fairly normally distributed, with a similar overall mean (0.876, SD = 0.188) and
median (0.930). An independent groups t-test showed no significant difference in MPR between
patients taking novel oral anticoagulants (0.880, SD = 0.182) and warfarin (0.873, SD = 0.194) (t
= -0.290; df = 268.948; p = 0.772).
Incidence of Major Bleeds
Incidence of major bleed (defined as a primary diagnosis code for a hemorrhagic event on
an inpatient medical claim) was assessed 12 months post-index.  Four patients (2.9%) in the
novel oral anticoagulant cohort experienced a major bleed 12 months post-index, while 7 patients
(5.1%) in the warfarin cohort experienced a major bleed. A chi-square analysis showed no
statistically significant relationship between incidence of major bleed and medication cohort (X2
= 0.853; df = 1; p = 0.356).
Incidence of Ischemic Stroke
Incidence of ischemic stroke (defined as a primary diagnosis code for ischemic stroke on
an inpatient medical claim) was assessed 12 months post-index. Three patients (2.2%) in the
novel oral anticoagulant cohort experienced an ischemic stroke 12 months post-index, while 1
patient (0.7%) in the warfarin cohort experienced an ischemic stroke. A chi-square analysis
showed no statistically significant relationship between incidence of ischemic stroke and
medication cohort (X2 = 1.015; df = 1; p = 0.314). However, in this analysis, 50% of cells had
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expected values less than 5, so the observed significance level based on chi-square distribution
cannot be relied upon.22
Direct Treatment Costs
Treatment costs analyzed for the 12 months post-index period are described in Table 3.3.
The sum of the total cost of the index medication was assessed during the 12 month post-index
period.  Overall, the sum of the index medication cost was found to be positively skewed with a
bimodal distribution pattern. A Mann-Whitney U test showed a significant difference in the sum
of the index medication costs between patients taking novel oral anticoagulants (median =
$3,051; mean = $2,658; SD = $1,494) and warfarin (median = $259; mean = $315; SD = $229)
(Z = -13.093; p <0.001).
Of the 136 patients meeting inclusion criteria for the warfarin cohort, costs of monitoring
warfarin via anticoagulation clinic in the 12 month post-index period were estimated from point-
of-care laboratory INR testing data retrievable from medical records. Each claim for INR testing
was multiplied by the estimated cost of $70.44.  Of the 136 patients, the range for the number of
tests was zero to 30, the mean number of tests was 10.6 and the median was 14.  About 30 % (n
= 40) of the warfarin patients did not have a claim for INR testing. The total INR monitoring cost
in the 12-month post-index period was found to be normally distributed with a mean of $751 (SD
= $599) and a median of $986.
The sum of the total cost of the index medication plus INR monitoring cost was assessed
during the 12 month post-index period.  Overall, the sum of the index medication cost plus INR
monitoring cost was found to be positively skewed with a bimodal distribution pattern. A Mann-
Whitney U test showed a significant difference in the sum of the index medication cost plus INR
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monitoring cost between patients taking novel oral anticoagulants (median = $3,084; mean =
$2,658; SD = $1,494) and warfarin (median = $1,171; mean = $1,066; SD = $633) (Z = -8.210; p
<0.001).
The sum of the costs to treat adverse events (based on primary diagnosis codes for
ischemic stroke or major bleed on inpatient medical claims) was assessed in the 12 month post-
index period. Overall, the sum of the costs to treat adverse events had a highly positively
skewed distribution pattern. A Mann-Whitney U test showed no significant difference in the
sum of the costs to treat an adverse event between patients taking novel oral anticoagulants
(median = $0; mean = $237; SD = $1,232) and warfarin (median = $0; mean = $283; SD =
$1,697) (Z = -0.269; p = 0.788). The range of estimated costs for the 8 patients in warfarin group
who had an event was $43 to $13,580 (mean = $4,815; total = $38,524), while for the 7 patients
in the novel agent group, the range was $31 to $8,325 (mean of $4,611; total = $32,283).
The sum of total costs of all-cause medical and pharmacy claims was assessed in the 12
month post-index period from Scott & White claims data.  Overall, the sum of total costs had a
positively skewed distribution pattern. A Mann-Whitney U test showed a significant difference
total cost between patients taking novel oral anticoagulants (median = $14,589; mean = $23,711;
SD = $22,910) and warfarin (median = $11,004; mean = $18,248; SD = $24,184) (Z = -3.603; p
<0.001).
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Table 3.3: Total Treatment Costs 12 Months Post-Index by Cohort (in 2014 U.S.
dollars)
Novel Anticoagulant
(n = 136)
Warfarin
(n = 136) p-value
Index Medicationa
mean (SD)
median
range
$2,658 ($1,494)
$3,084
$12 - $5,250
$315 ($229)
$259
$40 - $1,767
<0.001b
INR Monitoringc
mean (SD)
median
range
N/A $751 ($599)
$986
$0 - $2,113
N/A
Index Medication
+INR Monitoring
mean (SD)
median
range
$2,658 ($1,494)
$3,084
$12 - $5,250
$1,066 ($633)
$1,171
$58 - $3,035
<0.001d
Treating Adverse
Eventse
mean (SD)
median
range
$237 ($1,232)
$0
$0 - $8,325
$283 ($1,697)
$0
$0 – $13,580
0.788f
Total All-cause Costsg
mean (SD)
median
range
$23,711 ($22,910)
$14,589
$1,137 - $110,465
$18,248 ($24,184)
$11,004
$1,762 - $201,057
<0.001h
a; Estimated from 2014 per unit Average Wholesale Price (AWP) multiplied by unit quantity in claims
b Mann-Whitney U (Z = -13.093)
c Based on 2014 estimate of $70.44 total cost per claim for INR testing
d Mann-Whitney U (Z = -8.210)
e Based on total cost of inpatient claims for stroke or bleeds (n = 8 for warfarin cohort; n = 7 for novel anticoagulant
cohort) adjusted to 2014 estimates
f Mann-Whitney U (Z = -0.269)
g Based on total cost of all-cause claims adjusted to 2014 estimates
h Mann-Whitney U (Z = -3.603)
INR Control
Time in Therapeutic Range (TTR) was calculated to assess INR control (assuming an
INR theraputic range of 2.0 to 3.0) for the 136 patients who met inclusion criteria for the
warfarin cohort for all point-of-care laboratory INR testing data retrievable from medical
records. About 30% of patients (n = 40) did not have a claim for INR testing.  For the other 70%
(n = 96), TTR was found to range from 0% to 100% and was normally distributed with a mean of
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70.4% (SD = 20.4%) and a median of 70.8%, with half of patients having a TTR falling between
61.0% and 83.8%.
Summary
A summary of the results for each hypotheis is provided in Table 3.4.
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Table 3.4: Summary of Results by Hypothesis
Hypothesis Result
H01:  There is no statistical difference in patient
characteristics (age, gender, or CHADS2 score) between
patients taking novel oral anticoagulants (dabigatran or
rivaroxaban) versus clinic-monitored warfarin.
Age: not rejected
Gender: rejected: Higher
proportion males in novel cohort
CHADS2 = rejected; Lower
CHADS2 score for novel cohort
H02:  There is no statistical difference in patient adherence
to oral anticoagulant medication between patients taking
novel oral anticoagulants (dabigatran or rivaroxaban)
versus clinic-monitored warfarin.
MPR: not rejected
H03:  There is no statistical difference in the incidence of
major bleeds (requiring inpatient hospitalization) between
patients taking novel oral anticoagulants (dabigatran or
rivaroxaban) versus clinic-monitored warfarin.
Major bleed* = not rejected
H04:  There is no statistical difference in the incidence of
ischemic stroke between patients taking novel oral
anticoagulants (dabigatran or rivaroxaban) versus clinic-
monitored warfarin.
Ischemic Stroke* = not rejected
H05:  There is no statistical difference in total all-cause
direct treatment costs with novel oral anticoagulants
(dabigatran or rivaroxaban) compared to clinic-monitored
warfarin.
Direct treatment costs =
rejected; overall novel cohort
costs higher
*Low cell size, interpret with caution
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CHAPTER 4: DISCUSSION
Demographic Characteristics
The results of this study showed that prior to matching, patients taking dabigatran or
rivaroxaban were comparable in age to those taking warfarin.  Average age in this study was 76
years old, consistent with atrial fibrillation being a cardiac arrhythmia with increasing incidence
with age. There was a substantial difference in gender between the study cohorts, with about
two-thirds of patients taking dabigatran or rivaroxaban being male, while gender proportions
were nearly equal in the warfarin cohort. The study cohorts also differed in CHADS2 score, with
a mean CHADS2 of 2.65 in patients taking dabigatran or rivaroxaban compared with a mean
CHADS2 of 3.30 in patients taking warfarin, indicating that patients prescribed warfarin tended
to be at a greater risk of stroke based on past medical history. Baseline demographics were
comparable between study cohorts after matching, with 96% of patients in the novel oral
anticoagulant cohort having a comparable match in the warfarin cohort based on age, gender, and
CHADS2 score.
Anticoagulant Adherence
The results of this study showed comparable medication adherence between patients
taking dabigatran or rivaroxaban compared to patients taking warfarin. This is in contrast to the
notion that the advantage of fixed dosing and lack of laboratory monitoring with the newer oral
anticoagulants may lead to improved patient compliance. However, it’s important to note that
the warfarin patients in this study were followed by an Anticoagulation Clinic and may be more
motivated to be adherent to warfarin compared to patients not enrolled in an Anticoagulation
Clinic. Additionally, compared to relatively fixed dosing with dabigatran and rivaroxaban
31
therapy, days’ supply in the MPR calculation for warfarin is particularly affected by complex
dose regimens and regular dose adjustments with warfarin therapy and may therefore represent a
more rough estimation of patient adherence.
Incidence of Major Bleeds
The results of this study showed comparable incidence of major bleeds 12 months post-
index between patients taking dabigatran or rivaroxaban compared to patients taking warfarin.
This study found incidence of major bleeds to be 2.9% for patients taking dabigatran or
rivaroxaban, which is slightly less than the incidence found in the pivotal clinical trials for these
drugs; RE-LY showed an annual rate of major hemorrhage of 3.11% in dabigatran, and
ROCKET-AF showed an annual rate of major hemorrhage of 3.6% for rivaroxaban.12,13 This
study found an incidence of major bleeds to be 5.1% for patients taking warfarin, which is
greater than annual rate of major hemorrhage for warfarin found in the RE-LY and ROCKET-AF
trials (3.36% and 3.4%, respectively), although the definition of major bleeds in these studies
was based upon prospective clinical observation rather than administrative claims data.12,13 The
incidence of major bleeds  found in this study more closely mirror those of Darkow, et al., who
conducted a study with a similar definition of major bleeds based on ICD-9 codes on inpatient
administrative claims data, and found the occurrence of major hemorrhage with warfarin therapy
to be 4.4% within a 720-day follow-up period.23
However, the authors of this study note that the sample size was underpowered to detect a
difference between groups, therefore inferential statistics cannot be relied upon to draw
conclusions regarding incidence of major bleeds in this study.
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Incidence of Ischemic Stroke
The results of this study showed comparable incidence of ischemic stroke 12 months
post-index between patients taking dabigatran or rivaroxaban compared to patients taking
warfarin.  This study found incidence of ischemic stroke to be 2.2% for patients taking
dabigatran or rivaroxaban, which is slightly more than the incidence found in the pivotal clinical
trials for these drugs;  RE-LY showed an annual rate of stroke and systemic embolism of 1.11%
in dabigatran, and ROCKET-AF showed an annual rate of stroke and systemic embolism of
1.7% for rivaroxaban.12,13 This study found incidence of ischemic stroke to be 0.7% for patients
taking warfarin, which is less than annual rate of ischemic stroke for warfarin found in RE-LY,
ROCKET-AF, and less than the occurrence of ischemic stroke over a 720 day follow-up period
in an administrative claims study by Darkow et. al. (1.69%, 2.2%, and 3.7%, respectively).12,13,23
A meta-analysis of clinical trial data (including RE-LY and ROCKET-AF) showed an annual
risk of stroke or systemic embolism of 1.66% for patients with atrial fibrillation taking warfarin.9
However, the chi-square analysis in this study showed 50% of cells had expected values
less than 5, so the observed significance level based on chi-square distribution cannot be relied
upon.22 Additionally, the authors of this study note that the sample size was underpowered to
detect a difference between groups, therefore inferential statistics cannot be relied upon to draw
conclusions regarding incidence of ischemic stroke in this study.
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Direct Treatment Costs
As expected, this study showed a significant difference in the annual cost of the oral
anticoagulant medications based on average wholesale price (AWP), with warfarin
approximately one-tenth the cost of the newer agents, dabigatran and rivaroxaban. Cost of INR
monitoring was estimated from the perspective of the healthcare system, including the laboratory
fee, office visit fee, cost of INR testing supplies, and staff labor costs.  Total cost per patient per
visit was estimated at $70.44 in 2014 U.S. dollars. Applying this charge to each documented
INR visit in the warfarin cohort yielded an average annual monitoring cost of $751 per patient.
Due to inconsistencies in included cost parameters, annual INR monitoring costs vary widely in
previous studies, ranging from $291 to $943 in 2011 U.S. dollars.10 The results of this study
demonstrate that the annual cost of dabigatran or rivaroxaban is significantly greater than that of
warfarin, even when accounting for both medication and monitoring costs.
The results of this study showed comparable costs to treat adverse events (ischemic
stroke or major bleed) between patients taking dabigatran or rivaroxaban compared to patients
taking warfarin. However, the number of events in this study was too few for true comparison
between groups.
The results of this study show that patients taking dabigatran or rivaroxaban had greater
total annual healthcare costs (including all pharmacy and medical claims) compared to patients
taking warfarin. Given that there were too few adverse events to detect differences in related
costs between medication cohorts, and given that patients in this study were matched based on
age and CHADS2 score, it can be assumed that a substantial portion of this difference in total
annual healthcare costs is attributable to the significant difference in cost of the oral
anticoagulant medication.
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INR Control
The requirement of warfarin therapy to include frequent laboratory INR monitoring can
be burdensome to both clinicians and patients.  However, assessing the Time in Therapeutic
Range (TTR) of INRs for warfarin patients is an essential component of evaluating “real-world”
management of warfarin therapy, as the clinical and economic outcomes of warfarin therapy are
strongly dependent on the quality of anticoagulation control, as demonstrated by Sorensen et al.7
The model developed by Sorensen and colleagues showed that improved INR control lead to
decreased stroke rates and decreased per-patient costs.7 Additional studies have shown that
decreased TTR results in poorer outcomes, such as mortality, ischemic stroke,
thromboembolism, and major bleeding.4
The results of this study showed a mean TTR for warfarin patients was 70.4%. This
“real-world” TTR is greater than the typical TTR reported in controlled clinical trials ranging
from 55-66%, including the TTR found in RE-LY of 64% and the TTR in ROCKET-AF of
55%.9,12,13 Studies in community settings often report TTRs closer to 50%.9 The TTR found in
this study more closely mirrors the “trial-like control” TTR of 68% used in the model by
Sorensen et.al versus the “real-world control” TTR of 48%.7 The results of this study indicate
patients enrolled in the Scott & White Anticoagulation Clinics are particularly well managed on
warfarin therapy compared to previously reported findings in community settings, and the TTR
mirrors the anticoagulation control typically seen in clinical trial conditions. However, 30% of
patients in the warfarin cohort of this study did not have a claim for INR testing, presumably due
to INR monitoring occurring outside the Scott & White EMR system.
35
Study Limitations
Caution should be exercised when interpreting the results of this study due to several
limitations. Data were limited to a regional health system in a geographically distinct area,
which may limit the external validity of this study. Due to the retrospective nature of this study,
the results were reliant upon administrative claims data and EMR documentation.  Mis-coding of
ICD-9 codes or lack of submission of medical claims could limit the validity of results but would
not be expected to occur more frequently in one cohort over the other. Similarly, prescription
medication provided by physician offices as samples or purchased out-of-pocket by patients
(e.g., $4 generic drug lists) would not be captured in prescription claims data, and could have
affected cohort development and adherence calculations. INR laboratory data were extracted
from the EMR for an integrated healthcare system, and INR monitoring that occurred outside of
the system was not captured, possibly affecting TTR calculations.
Conclusions
The findings of this study demonstrate that significantly more men than women were
prescribed dabigatran or rivaroxaban compared to clinic-monitored warfarin, and patients
prescribed the newer oral anticoagulants averaged a lower CHADS2 score compared to warfarin
patients. Patient adherence to dabigatran or rivaroxaban was comparable to clinic-monitored
warfarin in this population. Anticoagulation control in this study was greater than previously
reported findings in community settings, with a TTR similar to clinical trials.
Annual medication cost of dabigatran or rivaroxaban was found to be significantly
greater than that of clinic-monitored warfarin, even when accounting for INR monitoring costs
with warfarin. Total annual healthcare costs were also significantly greater for patients taking
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dabigatran or rivaroxaban compared to warfarin, although there were too few adverse events in
this study to draw conclusions regarding event rates and treatment costs of ischemic stroke and
major bleeds.
Although the sample sizes and incidence rates of adverse events were low, comparison to
previous clinical trial and ‘real-world’ data is useful for future studies. As more novel oral
anticoagulants become available in the U.S. market as alternatives to warfarin for treatment of
atrial fibrillation, future studies will need to evaluate long-term clinical and economic outcomes
of these medications in larger patient populations. Decreased burden of INR monitoring is an
advantage of the new oral anticoagulants, and future research is needed to assess impact of these
agents on perceived quality of life. Additionally, this study focused on patients actively enrolled
in an Anticoagulation Clinic, and patient self-monitoring or physician monitoring was not
addressed.
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Appendix A:
CHADS2 Stroke-Risk Index – weights, diagnoses, and ICD-9 codes:
Weighta Diagnosesa ICD-9 codesb
1 Congestive heart failure 428.xx
1 Hypertension 401.xx – 405.xx
1 Age 75 years or older N/A
1 Diabetes mellitus 250.xx
2 History of stroke or transient ischemic attack 433.xx – 435.xx
ICD-9:  The International Classification of Diseases, 9th Revision, Clinical Modification
a Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke:
results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285:2864 –2870.
b Rothendler JA, Rose AJ, Reisman JI, et al.  Choices in the use of ICD-9 codes to identify stroke risk factors can
affect the apparent population-level risk factor prevalence and distribution of CHADS2 scores.  Am J Cardiovasc
Dis. 2012; 2(3):184-191.
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Appendix B:
Diagnosis Codes for Hemorrhagic Event
ICD-9 codesa Diagnosis Descriptiona
246.3 Hemorrhage and infarction of thyroid
285.1 Acute posthemorrhagic anemia
286.5 Hemorrhagic disorder due to circulating anticoagulants
331.3 Communicating hydrocephalus
362.81 Retinal hemorrhage
363.61, 363.62 Choroidal hemorrhage
372.72 Conjunctival hemorrhage
376.32 Orbital hemorrhage
379.23 Vitreous hemorrhage
380.31 Hematoma of auricle or pinna
423.0 Hemopericardium
430 Subarachnoid hemorrhage
431 Intracerebral hemorrhage
432.xx Other and unspecified intracranial hemorrhage
456.0, 456.20 Esophageal varices with bleeding
459.0 Hemorrhage, unspecified
530.82 Esophageal hemorrhage
531.0x, 531.2x Acute gastric ulcer with hemorrhage
531.4x, 531.6x Chronic or unspecified gastric ulcer with hemorrhage
532.0x, 532.2x Acute duodenal ulcer with hemorrhage
532.4x, 532.6x Chronic or unspecified duodenal ulcer with hemorrhage
533.0x, 533.2x Acute peptic ulcer with hemorrhage
533.4x, 533.6x Chronic or unspecified peptic ulcer with hemorrhage
534.0x, 534.2x Acute gastrojejunal ulcer with hemorrhage
534.4x, 534.6x Chronic or unspecified gastrojejunal ulcer with hemorrhage
535.x1 Gastritis and duodenitis with hemorrhage
537.83 Angiodysplasia of stomach and duodenum with hemorrhage
562.02, 562.03 Diverticulosis and diverticulitis of small intestine with hemorrhage
562.12, 562.13 Diverticulosis and diverticulitis of colon with hemorrhage
568.81 Hemoperitoneum
569.3 Hemorrhage of rectum and anus
569.85 Angiodysplasia of intestine with hemorrhage
578.x Gastrointestinal hemorrhage
596.7 Hemorrhage into bladder wall
602.1 Hemorrhage of prostate
621.4 Hematometra
623.6 Vaginal hematoma
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626.6 Metorrhageia
719.1x Hemarthrosis
782.7 Spontaneous ecchymoses
784.7 Epistaxis
784.8 Hemorrhage from throat
786.3 Hemoptysis
997.02 Iatrogenic cerebrovascular infarction or hemorrhage
E934.2 Adverse effects related to therapeutic use of anticoagulants
ICD-9:  The International Classification of Diseases, 9th Revision, Clinical Modification
a Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in
nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin. 2005; Oct:21(10):1583-94.
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